Markers of β cell function in type 1 diabetes mellitus

F. Vendrame, A. Zappaterreno, F. Dotta

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Type 1 diabetes mellitus is a multifactorial autoimmune disease characterized by destruction of insulin producing pancreatic β cells that results in insulin deficiency and fasting hyperglycemia. It is now well known that the clinical onset of the disease represents the end stage of an immunological process that occurs over a course of months to years. During this period the presence of autoantibodies against different islet antigens can be detected by the use of standardized assays. The rate of β cell loss is quite variable among different individuals and at onset ketoacidosis represents still a life threatening complication of the disease. The Diabetes Control and Complication Trial (DCCT) has clear ly shown that the preservation of β cell function in type 1 diabetic subjects results in a better metabolic control and significantly reduces the risk of microvascular complications. Consequently, markers of β cell function represent important tools to make an early diagnosis and to evaluate the impact of new therapies on the natural history of the disease. The present review will focus on clinical markers currently available (intravenous glucose tolerance test, IVGTT, oral glucose tolerance test, OGTT, basal and stimulated C-peptide) to assess the β cell function in type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)79-84
Number of pages6
JournalMinerva Medica
Issue number2
StatePublished - Apr 2004
Externally publishedYes


  • Diabetes mellitus, type 1
  • Insulin, metabolism
  • Islets of Langerhans

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Markers of β cell function in type 1 diabetes mellitus'. Together they form a unique fingerprint.

Cite this